Find Research Outputs

Search concepts
Selected filters

Publication Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Author

  • Richard Kefford
2013

Reply to K.S. Wilson et al

Ribas, A., Hauschild, A. & Kefford, R., 1 Aug 2013, In : Journal of Clinical Oncology. 31, 22, p. 2836-2837 2 p.

Research output: Contribution to journalLetter

8 Citations (Scopus)
2014

Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475

Kefford, R., Ribas, A., Hamid, O., Robert, C., Daud, A., Wolchok, J. D., Joshua, A. M., Hodi, F. S., Gangedher, T. C., Hersey, P., Weber, J. S., Dronca, R. S., Patnaik, A., Zarour, H. M., Dolled-Filhart, M., Lunceford, J., Emancipator, K., Ebbinghaus, S., Rang, S. P. & Hwu, W-J., 20 May 2014, In : Journal of Clinical Oncology. 32, 15 supplement, p. 3005 1 p.

Research output: Contribution to journalMeeting abstract

35 Citations (Scopus)
2018

Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Haas, T., Shilkrut, M., Gasal, E. & 3 others, Kefford, R., Kirkwood, J. M. & Long, G. V., 10 Dec 2018, In : Journal of Clinical Oncology. 36, 35, p. 3441-3449+ 13 p.

Research output: Contribution to journalArticle

Open Access
File
62 Citations (Scopus)
19 Downloads (Pure)
2017

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma

Helgadottir, H., Kis, L., Ljungman, P., Larkin, J., Kefford, R., Ascierto, P. A., Hansson, J. & Masucci, G., 1 Jul 2017, In : Annals of oncology : official journal of the European Society for Medical Oncology. 28, 7, p. 1672-1673 2 p.

Research output: Contribution to journalArticle

24 Citations (Scopus)
2020
Open Access
File
2 Downloads (Pure)
2018

Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma

Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W. J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., Dronca, R., Patnaik, A., Zarour, H., Kefford, R., Hersey, P., Zhang, J., Anderson, J., Diede, S. J., Ebbinghaus, S. & Hodi, F. S., 10 Jun 2018, In : Journal of Clinical Oncology. 36, 17, p. 1668-1674 7 p.

Research output: Contribution to journalArticle

111 Citations (Scopus)
2011

Genome-wide association study identifies novel loci predisposing to cutaneous melanoma

Amos, C. I., Wang, L. E., Lee, J. E., Gershenwald, J. E., Chen, W. V., Fang, S., Kosoy, R., Zhang, M., Qureshi, A. A., Vattathil, S., Schacherer, C. W., Gardner, J. M., Wang, Y., Tim bishop, D., Barrett, J. H., Macgregor, S., Hayward, N. K., Martin, N. G., Duffy, D. L., Mann, G. J. & 55 others, Cust, A., Hopper, J., Brown, K. M., Grimm, E. A., Xu, Y., Han, Y., Jing, K., Mchugh, C., Laurie, C. C., Doheny, K. F., Pugh, E. W., Seldin, M. F., Han, J., Wei, Q., Mann, G. J., Hopper, J. L., Aitken, J. F., Armstrong, B. K., Giles, G. G., Kefford, R. F., Cust, A. E., Jenkins, M. A., Schmid, H., Aguilera, P., Badenas, C., Carrera, C., Cuellar, F., Gabriel, D., Martinez, E., Gonzalez, M., Iglesias, P., Malvehy, J., Marti-Laborda, R., Mila, M., Ogbah, Z., Puig Butille, J. A., Puig, S., Alós, L., Arance, A., Arguís, P., Campo, A., Castel, T., Conill, C., Palou, J., Rull, R., Sánchez, M., Vidal-Sicart, S., Vilalta, A., Vilella, R., Martin, N. G., Montgomery, G. W., Duffy, D. L., Whiteman, D. C., MacGregor, S. & Hayward, N. K., Dec 2011, In : Human molecular genetics. 20, 24, p. 5012-5023 12 p., ddr415.

Research output: Contribution to journalArticle

129 Citations (Scopus)
2012

Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma

Weber, J. S., Flaherty, K. T., Infante, J. R., Falchook, G. S., Kefford, R., Daud, A., Hamid, O., Gonzalez, R., Kudchadkar, R. R., Lawrence, D. P., Burris, H. A., Long, G. V., Algazi, A. P., Lewis, K. D., Kim, K. B., Puzanov, I., Sun, P., Little, S. M., Patel, K. & Sosman, J. A., 20 May 2012, In : Journal of Clinical Oncology. 30, Supplement 15, p. 8510-8510 1 p.

Research output: Contribution to journalMeeting abstract

2011

BRAF mutation by age-decade and body mass index in metastatic melanoma

Menzies, A. M., Visintin, L., Chatfield, M. D., Carlino, M. S., Howle, J. R., Scolyer, R. A., Thompson, J. F., Kefford, R. F. & Long, G. V., 20 May 2011, In : Journal of Clinical Oncology. 29, 15, p. 8507-8507 1 p.

Research output: Contribution to journalMeeting abstract

2016

Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE study

Fox, P., Balleine, R. L., Lee, C., Gao, B., Balakrishnar, B., Menzies, A. M., Yeap, S. H., Ali, S. S., Gebski, V., Provan, P., Coulter, S., Liddle, C., Hui, R., Kefford, R., Lynch, J., Wong, M., Wilcken, N. & Gurney, H., 1 Jul 2016, In : Clinical Cancer Research. 22, 13, p. 3164-3171 8 p.

Research output: Contribution to journalArticle

29 Citations (Scopus)
2015

Patient adherence to aromatase inhibitor treatment in early stage breast cancer - local experience from western Sydney hospitals

Cuan, S., Gao, B., Hui, R. & Kefford, R., Nov 2015, In : Asia-Pacific Journal of Clinical Oncology. 11, S4, p. 120-120 1 p.

Research output: Contribution to journalMeeting abstract

2012

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Kudchadkar, R., Burris, H. A., Falchook, G., Algazi, A., Lewis, K., Long, G. V., Puzanov, I., Lebowitz, P., Singh, A., Little, S. & 6 others, Sun, P., Allred, A., Ouellet, D., Kim, K. B., Patel, K. & Weber, J., 1 Nov 2012, In : New England Journal of Medicine. 367, 18, p. 1694-1703 10 p.

Research output: Contribution to journalArticle

1754 Citations (Scopus)
2015

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature

Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W-J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., Albright, A., Kang, S. P., Ebbinghaus, S., Yearley, J., Murphy, E., Nebozhyn, M., Lunceford, J. K., McClanahan, T., Ayers, M. & Daud, A., 20 May 2015, In : Journal of Clinical Oncology. 33, 15 supplement, p. 3001 1 p.

Research output: Contribution to journalMeeting abstract

2013

Somatic mutations in metastatic melanoma in a large cohort of Australian patients

Lyle, M., Menzies, A. M., Guminski, A., Saw, R. P. M., Stretch, J. R., Shannon, K. F., Spillane, A. J., Thompson, J. F., Howle, J. R., McNeil, C., Hersey, P., Kefford, R. F., Mann, G. J., Scolyer, R. A., O'Toole, S., Haydu, L. E. & Long, G. V., Nov 2013, In : Asia-Pacific Journal of Clinical Oncology. 9, Supplement S3, p. 76-76 1 p., 52.

Research output: Contribution to journalMeeting abstract

2011

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)

Infante, J. R., Falchook, G. S., Lawrence, D. P., Weber, J. S., Kefford, R. F., Bendell, J. C., Kurzrock, R., Shapiro, G., Kudchadkar, R. R., Long, G. V., Burris, H. A., Kim, K. B., Clements, A., Peng, S., Yi, B., Allred, A. J., Ouellet, D., Patel, K., Lebowitz, P. F. & Flaherty, K. T., 20 Jun 2011, In : Journal of Clinical Oncology. 29, 18, p. CRA8503 1 p.

Research output: Contribution to journalMeeting abstract

2012

MC1R genotypes and risk of melanoma before age 40 years: A population-based case-control-family study

Cust, A. E., Goumas, C., Holland, E. A., Agha-Hamilton, C., Aitken, J. F., Armstrong, B. K., Giles, G. G., Kefford, R. F., Schmid, H., Hopper, J. L., Mann, G. J. & Jenkins, M. A., 1 Aug 2012, In : International Journal of Cancer. 131, 3, p. E269-E281 13 p.

Research output: Contribution to journalReview article

21 Citations (Scopus)
2013

BRAF inhibitor activity in V600R metastatic melanoma-Response

Klein, O., Clements, A., Menzies, A. M., O'Toole, S., Kefford, R. F. & Long, G. V., May 2013, In : European Journal of Cancer. 49, 7, p. 1797-1798 2 p.

Research output: Contribution to journalLetter

13 Citations (Scopus)
2015

Factors influencing the development of cutaneous squamous cell carcinomas in patients on BRAF inhibitor therapy

Anforth, R., Menzies, A., Byth, K., Carlos, G., Chou, S., Sharma, R., Scolyer, R. A., Kefford, R., Long, G. V. & Fernandez-Penas, P., May 2015, In : Australasian Journal of Dermatology. 56, s2, p. 21-22 2 p.

Research output: Contribution to journalMeeting abstract

2014

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas

Kakavand, H., Crainic, O., Lum, T., O'Toole, S. A., Kefford, R. F., Thompson, J. F., Wilmott, J. S., Long, G. V. & Scolyer, R. A., 2014, In : Pathology. 46, 3, p. 193-198 6 p.

Research output: Contribution to journalArticle

14 Citations (Scopus)
2017

Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma

Delord, J. P., Robert, C., Nyakas, M., McArthur, G. A., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R. F., Carlino, M. S., Hidalgo, M., Gomez-Roca, C., Michel, D., Seroutou, A., Aslanis, V., Caponigro, G., Stuart, D. D., Moutouh-De Parseval, L., Demuth, T. & 1 others, Dummer, R., 15 Sep 2017, In : Clinical Cancer Research. 23, 18, p. 5339-5348 10 p.

Research output: Contribution to journalArticle

43 Citations (Scopus)
2011

Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3

MacGregor, S., Montgomery, G. W., Liu, J. Z., Zhao, Z. Z., Henders, A. K., Stark, M., Schmid, H., Holland, E. A., Duffy, D. L., Zhang, M., Painter, J. N., Nyholt, D. R., Maskiell, J. A., Jetann, J., Ferguson, M., Cust, A. E., Jenkins, M. A., Whiteman, D. C., Olsson, H., Puig, S. & 32 others, Bianchi-Scarrà, G., Hansson, J., Demenais, F., Landi, M. T., Dȩbniak, T., MacKie, R., Azizi, E., Bressac-De Paillerets, B., Goldstein, A. M., Kanetsky, P. A., Gruis, N. A., Elder, D. E., Newton-Bishop, J. A., Bishop, D. T., Iles, M. M., Helsing, P., Amos, C. I., Wei, Q., Wang, L. E., Lee, J. E., Qureshi, A. A., Kefford, R. F., Giles, G. G., Armstrong, B. K., Aitken, J. F., Han, J., Hopper, J. L., Trent, J. M., Brown, K. M., Martin, N. G., Mann, G. J. & Hayward, N. K., Nov 2011, In : Nature Genetics. 43, 11, p. 1114-1118 5 p.

Research output: Contribution to journalArticle

106 Citations (Scopus)
2015

A pooled analysis of 655 patients with advanced melanoma enrolled in KEYNOTE-001: long-term efficacy of pembrolizumab (MK-3475)

Daud, A., Joshua, A. M., Ribas, A., Robert, C., Hodi, F. S., Wolchok, J., Hwu, W-J., Weber, J. S., Gangadhar, T. C., Joseph, R., Dronca, R., Patnaik, A., Zarour, H., Kefford, R., Lindia, J., Li, X. N., Ebbinghaus, S., Kang, S. P. & Hamid, O., Aug 2015, In : Asia-Pacific Journal of Clinical Oncology. 11, p. 43-43 1 p.

Research output: Contribution to journalMeeting abstract

2016

Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Manders, P., Joshua, A. M., Gangadhar, T. C., Joseph, R., Dronca, R., Patnaik, A., Zarour, H., Hersey, P., Li, X. N., Diede, S. J., Ebbinghaus, S., Hodi, F. S., Kefford, R., Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Hwu, W-J. & Weber, J. S., Aug 2016, In : Asia-Pacific journal of clinical oncology, volume 12 supplement 4 : Medical Oncology Group of Australia incorporated annual scientific meeting : program and abstracts. 12, p. 47-48 2 p.

Research output: Contribution to journalMeeting abstract

2014

Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475

Joseph, R. W., Elassaiss-Schaap, J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, M., Robert, C., Daud, A., Hwu, W-J., Kefford, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P., Perrone, A. M., Kang, S. P., Ebbinghaus, S., Anderson, K. M. & Gangadhar, T. C., 20 May 2014, In : Journal of Clinical Oncology. 32, 15, p. 3015 1 p.

Research output: Contribution to journalMeeting abstract

2012

Pharmacokinetics and pharmacodynamics of a selective oral MEK1/2 inhibitor, pimasertib (MSC1936369B/AS703026), in patients with advanced Solid tumors

Houede, N., Delord, J. P., Awada, A., Lebbe, C., Lesimple, T., Schellens, J. H. M., Rottey, S., Kefford, R., von Richter, O. & Raymond, E., Nov 2012, In : European Journal of Cancer. 48, p. 184-184 1 p., 600.

Research output: Contribution to journalMeeting abstract

2013

Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation

Fox, P., Gao, B., Balakrishnar, B., Menzies, A. M., Yeap, S. H., Ali, S. S., Gebski, V., Provan, P., Coulter, S., Liddle, C., Hui, R., Kefford, R., Lynch, J., Wilcken, N., Balleine, R. L. & Gurney, H., 20 May 2013, In : Journal of Clinical Oncology. 31, 15 supplement, p. 1-1 1 p., 543.

Research output: Contribution to journalMeeting abstract

19 Citations (Scopus)
2011

BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma

Ribas, A., Kim, K. B., Schuchter, L. M., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Flaherty, K. T., Moschos, S. J., Lawrence, D. P., Hersey, P., Kefford, R. F., Chmielowski, B., Puzanov, I., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K. & Sosman, J. A., 20 May 2011, In : Journal of Clinical Oncology. 29, 15, p. 8509 1 p., 8509.

Research output: Contribution to journalMeeting abstract

2013

Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

Chan, M., Haydu, L., Menzies, A. M., Azer, M. W. F., Klein, O., Guminski, A., Kefford, R. & Long, G., 20 May 2013, In : Journal of Clinical Oncology. 31, 15, p. 9062-9062 1 p.

Research output: Contribution to journalMeeting abstract

2014

Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

Anforth, R., Liu, M., Nguyen, B., Uribe, P., Kefford, R., Clements, A., Long, G. V. & Fernandez-Peñas, P., 1 Nov 2014, In : Australasian Journal of Dermatology. 55, 4, p. 250-254 5 p.

Research output: Contribution to journalArticle

27 Citations (Scopus)

Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome

Daud, A. I., Hamid, O., Ribas, A., Hodi, F. S., Hwu, W-J., Kefford, R., Wolchok, J., Hersey, P., Weber, J. S., Joseph, R., Gangadhar, T. C., Dronca, R. S., Patnaik, A., Zarour, H., Joshua, A. M., Gergich, K., Wu, D., Lunceford, J. K., Emancipator, K., Dolled-Filhart, M. & 4 others, Li, N., Ebbinghaus, S., Kang, S. P. & Robert, C., 30 Sep 2014, In : Cancer Research. 74, 19, 1 p., CT104.

Research output: Contribution to journalMeeting abstract

2013

Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)

Cebon, J. S., Flaherty, K., Weber, J. S., Kim, K., Infante, J. R., Daud, A., Hamid, O., Kefford, R., Schuchter, L. M., Sosman, J. A., Sznol, M., Sharfman, W. H., Gonzalez, R., Andrews, M. C., Dronca, R. S., Long, G., Little, S. M., Sun, P., Patel, K. & McWilliams, R. R., 20 May 2013, In : Journal of Clinical Oncology. 31, 15 supplement, p. 9016-9016 1 p.

Research output: Contribution to journalMeeting abstract

2015

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Hersh, E. M., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R., Haydon, A., Robert, C., Ernst, S., Homsi, J., Grob, J. J., Kendra, K., Agarwala, S. S., Li, M., Clawson, A., Brachmann, C., Karnoub, M. & 3 others, Elias, I., Renschler, M. F. & Hauschild, A., 1 Nov 2015, In : Annals of Oncology. 26, 11, p. 2267-2274 8 p., mdv324.

Research output: Contribution to journalArticle

28 Citations (Scopus)
2012

Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

Awada, A., Delord, J. P., Houede, N., Lebbe, C., Lesimple, T., Schellens, J. H. M., Rottey, S., Kefford, R., Rejeb, N. & Raymond, E., Nov 2012, In : European Journal of Cancer. 48, p. 185-186 2 p., 604.

Research output: Contribution to journalMeeting abstract

2013

Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors

Kefford, R., Miller, W. H., Tan, D. S-W., Sullivan, R. J., Long, G., Dienstmann, R., Tai, W. M. D., Flaherty, K., Stutvoet, S., Schumacher, K. M., Wandel, S., De Parseval, L. A. & Tabernero, J., 20 May 2013, In : Journal of Clinical Oncology. 31, Supplement 15, p. 9029-9029 1 p.

Research output: Contribution to journalMeeting abstract

2015

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

Menzies, A. M., Wilmott, J. S., Drummond, M., Lo, S., Lyle, M., Chan, M. M. K., Thompson, J. F., Guminski, A., Carlino, M. S., Scolyer, R. A., Kefford, R. F. & Long, G. V., 1 Nov 2015, In : Cancer. 121, 21, p. 3826-3835 10 p.

Research output: Contribution to journalArticle

30 Citations (Scopus)
1 Downloads (Pure)
2013

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma

Long, G. V., Wilmott, J. S., Capper, D., Preusser, M., Zhang, Y. E., Thompson, J. F., Kefford, R. F., Von Deimling, A. & Scolyer, R. A., Jan 2013, In : American Journal of Surgical Pathology. 37, 1, p. 61-65 5 p.

Research output: Contribution to journalArticle

214 Citations (Scopus)
2014

Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM)

Lyle, M. K., Lee, J. HJ., Menzies, A. M., Chan, M. M. K., Clements, A., Carlino, M. S., Kefford, R. & Long, G. V., 20 May 2014, In : Journal of Clinical Oncology. 32, 15_suppl, p. 1-1 1 p., 9077.

Research output: Contribution to journalMeeting abstract

24 Citations (Scopus)
2012

Drug treatment for melanoma: Progress, but who pays?

Kefford, R. F., Aug 2012, In : Medical Journal of Australia. 197, 4, p. 198-199 2 p.

Research output: Contribution to journalEditorial

10 Citations (Scopus)
2014
2013

Intravascular metastatic melanoma: A difficult diagnosis

Ghattas, S., Howle, J., Wang, W., Kefford, R. & Gruenewald, S., May 2013, In : Australasian Journal of Dermatology. 54, 2, p. 141-143 3 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)
2012

Clinical Status of RAF/MEK Inhibitors

Weber, J., Daud, A., Infante, J., Sosman, J., Flaherty, K., Kefford, R., Hamid, O., Schuchter, L., Patel, K. & Gonzalez, R., Nov 2012, In : European Journal of Cancer. 48, Supplement 6, p. 10-10 1 p., 23.

Research output: Contribution to journalMeeting abstract

2015

Immune checkpoint inhibitors in melanoma

Cooper, A. J., Carlino, M. S. & Kefford, R. F., Aug 2015, In : Melanoma Management. 2, 3, p. 267-284 18 p.

Research output: Contribution to journalReview article

1 Citation (Scopus)
2019

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R. & 3 others, Dummer, R., Kirkwood, J. M. & Long, G. V., 1 May 2019, In : The Lancet Oncology. 20, 5, p. 701-710 10 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)
2012

Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436)

Azer, M. W. F., Menzies, A. M., Haydu, L., Kefford, R. & Long, G. V., 20 May 2012, In : Journal of Clinical Oncology. 30, Supplement 15, p. 550-550 1 p.

Research output: Contribution to journalMeeting abstract

2014

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma

Lee, C. I., Menzies, A. M., Haydu, L. E., Azer, M., Clements, A., Kefford, R. F. & Long, G. V., 1 Oct 2014, In : Melanoma Research. 24, 5, p. 468-474 7 p.

Research output: Contribution to journalArticle

24 Citations (Scopus)

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W. H., McWilliams, R. R., Sznol, M., Lawrence, D. P., Gibney, G. T., Burris, H. A., Falchook, G. S., Algazi, A., Lewis, K., Long, G. V., Patel, K. & 7 others, Ibrahim, N., Sun, P., Little, S., Cunningham, E., Sosman, J. A., Daud, A. & Gonzalez, R., 20 Nov 2014, In : Journal of Clinical Oncology. 32, 33, p. 3697-3704 8 p.

Research output: Contribution to journalArticle

124 Citations (Scopus)

The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma

Dummer, R., Flaherty, K., Kefford, R., Ascierto, P. A., Moutouh-de Parseval, L., Wasserman, E. & Schadendorf, D., Sep 2014, In : British Journal of Dermatology. 171, 3, p. e80-e80 1 p., 150 (PP17).

Research output: Contribution to journalMeeting abstract

2016

Differences in the patterns of anti-pd1 (PD1) toxicity between tumor streams

Sabanathan, D., Kong, B., Byrne, N., Wegener, V., Eslick, G., Nagrial, A., Hui, R., Kefford, R., Gurney, H. & Carlino, M. S., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S4, p. 68-68 1 p.

Research output: Contribution to journalMeeting abstract

2012

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P. & Scolyer, R. A., 1 Mar 2012, In : Clinical Cancer Research. 18, 5, p. 1386-1394 9 p.

Research output: Contribution to journalArticle

393 Citations (Scopus)